Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TP2F
- Development stage
- Unknown
- Lead developer
- Centre Antoine Lacassagne
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
TP2F (also referred to as TPF2) is an induction chemo-immunotherapy regimen consisting of the standard TPF triplet chemotherapy—docetaxel (Taxotere), cisplatin (Platinol), and 5-fluorouracil (5-FU)—combined with the PD-1 immune checkpoint inhibitor pembrolizumab (Keytruda). Developed and evaluated by the Centre Antoine Lacassagne, this combination is specifically investigated as an induction therapy for patients with untreated, locally-advanced, unresectable head and neck squamous cell carcinoma (HNSCC). The regimen is designed to leverage the cytotoxic effects of chemotherapy to reduce tumor burden and potentially enhance the immune response triggered by pembrolizumab prior to definitive treatment with radiotherapy and carboplatin.
- Other names
- docetaxel + cisplatin + 5-fluorouracil + pembrolizumabTPF + pembrolizumab
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on TP2F.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TP2F.